<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">DIPHTHERIA</span> AND <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> TOXOIDS ADSORBED- corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) and clostridium tetani toxoid antigen (formaldehyde inactivated) injection, suspension </strong><br>Sanofi Pasteur Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed safely and effectively. See full prescribing information for <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed.<br><br> <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed<br> Suspension for Intramuscular Injection<br> Initial U.S. Approval: 1997</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="90%">
<col align="left" valign="top" width="65%">
<col align="right" valign="top" width="35%">
<tbody class="Headless">
<tr>
<td align="left">Warnings &amp; Precautions:</td>
<td align="right"></td>
</tr>
<tr>
<td align="left"><ul class="Square">
<li><span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span> in premature infants (<a href="#S5.5">5.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> (<a href="#S5.6">5.6</a>)</li>
</ul></td>
<td align="right">6/2013<br>6/2013</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed is a vaccine indicated for active immunization against <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>. <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed is approved for use in children from 6 weeks through 6 years of age (prior to 7<span class="Sup">th</span> birthday). (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">The five dose immunization series consists of an injection administered at 2, 4, 6, 15-18 months and between 4 and 6 years of age. (<a href="#S2.1">2.1</a>) </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Suspension for injection, supplied in single dose (0.5 mL) vials (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) after a previous dose of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed or any other <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid or <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine, or any other component of this vaccine. (<a href="#S4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Square">
<li>If Guillain-Barré syndrome occurred within 6 weeks of receipt of prior vaccine containing <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid, the risk for Guillain-Barré syndrome may be increased following <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed vaccine. (<a href="#S5.2">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span> following intramuscular vaccination has been observed in some infants born prematurely. The decision about when to administer an intramuscular vaccine, including <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed, to an infant born prematurely should be based on consideration of the individual infant's medical status and the potential benefits and possible risks of vaccination. (<a href="#S5.5">5.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> (<span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>) has been reported following vaccination with <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed vaccine. Procedures should be in place to prevent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> injury and manage syncopal reactions. (<a href="#S5.6">5.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (≥5%) were <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and loss of appetite. (<a href="#S6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sanofi Pasteur Inc., at 1-800-822-2463 (1-800-VACCINE) or VAERS at 1-800-822-7967 and http://vaers.hhs.gov.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Immunosuppressive therapies may reduce the response to <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed. (<a href="#S7.3">7.3</a>) </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div><div></div></div></div>
<div></div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 7/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	 	Dosage and Schedule</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	 	Administration </a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Management of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Acute Allergic Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Guillain-Barré Syndrome and Brachial <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">Neuritis</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3  Limitation of Vaccine Effectiveness</a></h2>
<h2><a href="#section-5.4" class="toc">5.4  Altered Immunocompetence</a></h2>
<h2><a href="#section-5.5" class="toc">5.5	<span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span> in Premature Infants</a></h2>
<h2><a href="#section-5.6" class="toc">5.6	<span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1  Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Concomitant Administration With Other Vaccines</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Concomitant Administration with <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Immune Globulin (Human)</a></h2>
<h2><a href="#section-7.3" class="toc">7.3	Immunosuppressive Treatments</a></h2>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.4 	Pediatric Use</a></h2>
<h1><a href="#section-9" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action</a></h2>
<h1><a href="#section-11" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">14	CLINICAL STUDIES</a></h1>
<h1><a href="#section-13" class="toc">15	REFERENCES</a></h1>
<h1><a href="#section-14" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed is a vaccine indicated for active immunization against <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>. <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed is approved for use in children from 6 weeks through 6 years of age (prior to 7<span class="Sup">th</span> birthday).</p>
<p><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine (DTaP) or a DTaP-containing vaccine is recommended for immunization of infants and children 6 weeks through 6 years of age. <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed should be used in instances where the <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> vaccine component is contraindicated.</p>
<p><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed is not to be used for treatment of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> or <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">For intramuscular use only.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	 	Dosage and Schedule</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed is approved for administration as a 5 dose series at 2, 4, 6, 15-18 months, and 4-6 years. The first dose of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed may be administered as early as 6 weeks of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	 	Administration </h2>
<p class="First">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If these conditions exist, the product should not be administered.</p>
<p>After removing the "flip-off" cap, cleanse the vaccine vial stopper with a suitable germicide. Do not remove either the rubber stopper or the metal seal holding it in place. Just before use, shake the vial well until a uniform, white, cloudy suspension results.</p>
<p>Using a sterile needle and syringe and aseptic technique, withdraw and administer a single 0.5 mL dose of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed intramuscularly. Use a separate sterile needle and syringe for each injection. Changing needles between withdrawing the vaccine from the vial and injecting it into a recipient is not necessary unless the needle has been damaged or contaminated. In infants younger than 1 year, the anterolateral aspect of the thigh provides the largest muscle and is the preferred site of injection. In older children, the deltoid muscle is usually large enough for injection. The vaccine should not be injected into the gluteal area or areas where there may be a major nerve trunk.</p>
<p><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed vaccine should not be combined through reconstitution or mixed with any other vaccine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed is a suspension for injection in 0.5 mL single dose vials.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<p class="First">A severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) after a previous dose of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed or any other <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid or <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine, or any other component of this vaccine is a contraindication to administration of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed. [See <span class="Italics"><a href="#S11">Description (11)</a>.</span>]</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Management of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Acute Allergic Reactions</span></h2>
<p class="First">Epinephrine Injection (1:1000) and other appropriate agents and equipment must be available for immediate use in case an anaphylactic or acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Guillain-Barré Syndrome and Brachial <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">Neuritis</span></h2>
<p class="First">A review by the Institute of Medicine (IOM) found evidence for a causal relation between <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid and both brachial <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span> and Guillain-Barré syndrome. (1) If Guillain-Barré syndrome occurred within 6 weeks of receipt of prior vaccine containing <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid, the risk for Guillain-Barré syndrome may be increased following <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed vaccine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3  Limitation of Vaccine Effectiveness</h2>
<p class="First">Vaccination with <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed may not protect all individuals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4  Altered Immunocompetence</h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed vaccine is administered to immunocompromised persons, including persons receiving immunosuppressive therapy, the expected immune response may not be obtained. [See <span class="Italics"><a href="#S7.3">Immunosuppressive Treatments (7.3)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	<span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span> in Premature Infants</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span> following intramuscular vaccination has been observed in some infants born prematurely. The decision about when to administer an intramuscular vaccine, including <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed, to an infant born prematurely should be based on consideration of the individual infant's medical status and the potential benefits and possible risks of vaccination.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	<span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> (<span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>) has been reported following vaccination with <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed vaccine. Procedures should be in place to prevent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> injury and manage syncopal reactions.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<p class="First">The most common adverse reactions (≥5%) were <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and loss of appetite.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1  Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to vaccine use and for approximating rates of those events.</p>
<p>In a clinical trial in Baltimore, 163 infants received <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed at 2, 4 and 6 months of age. The results of this trial are presented in Table 1.</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1: Percentage of Children Experiencing Local and Systemic Reactions at 24 Hours Following Immunization</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2" valign="bottom">Reaction</th>
<th class="Rrule" align="center" colspan="3">BALTIMORE<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><br>(N=163)</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">Dose 1<br>(%)<br>(n = 155)</th>
<th class="Rrule" align="center">Dose 2<br>(%)<br>(n = 145)</th>
<th class="Rrule" align="center">Dose 3<br>(%)<br>(n = 136)</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>A total of 163 children received one of the three lots of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed at 2, 4, and 6 months of age, and acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> vaccine at 3, 5, and 7 months of age. One control group (N=85) received <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed concurrently at a separate site with acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> vaccine at 2, 4 and 6 months of age (data not shown). A second control group (N=85) received commercial DTwP vaccine at 2, 4, and 6 months of age, and a placebo at 3, 5, and 7 months of age (data not shown).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">Systemic Reactions</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> ≥38°C &lt;39°C (≥100.4°F &lt;102.2°F)</td>
<td class="Rrule" align="center">0.7</td>
<td class="Rrule" align="center">0.8</td>
<td class="Rrule" align="center">6.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> ≥39°C (≥102.2°F )</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">Crying</span></td>
<td class="Rrule" align="center">13.6</td>
<td class="Rrule" align="center">15.2</td>
<td class="Rrule" align="center">13.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Loss of Appetite</td>
<td class="Rrule" align="center">3.9</td>
<td class="Rrule" align="center">6.2</td>
<td class="Rrule" align="center">2.9</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection Site Reactions</span> </span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Redness</span> ≥2.5 cm</td>
<td class="Rrule" align="center">0.7</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Slight <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="center">2.6</td>
<td class="Rrule" align="center">2.8</td>
<td class="Rrule" align="center">2.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Moderate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="center">0.7</td>
<td class="Rrule" align="center">1.4</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">Hardness ≥2.5 cm</td>
<td class="Rrule" align="center">1.3</td>
<td class="Rrule" align="center">1.4</td>
<td class="Rrule" align="center">3.6</td>
</tr>
</tbody>
</table>
<p>Two clinical trials were conducted in Canada. In the first clinical trial, 52 children aged 17-22 months who had previously received 3 doses of whole-cell DTP Adsorbed vaccine (not licensed in US), received <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed with either an acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> (n = 25) or a whole cell <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> (n = 27) vaccine (neither licensed in US) given concurrently but at a separate site. The only reported local reaction was slight <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at the <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed injection site in 11% of children.</p>
<p>In a second clinical trial conducted in Canada, 99 children aged 4 to 6 years old who were eligible for the preschool (fifth) dose of DTP received <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed in one arm and a whole-cell Monovalent <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> vaccine (not licensed in US) in the other. The following local reactions at the <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed injection site were reported: <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> ≥50 mm - 9%, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> &gt;50 mm - 51%, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, moderate or severe - 17%, arm mobility "too sore to move" - 9%. (2)</p>
<p><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed evaluated in clinical trials contained thimerosal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">The following adverse events have been spontaneously reported during the postmarketing use of a <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed vaccine manufactured by Sanofi Pasteur Limited that contained thimerosal. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure.</p>
<p>The following adverse events were included based on severity, frequency of reporting or the strength of causal association with <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed:</p>
<p><span class="Bold Italics">Blood and lymphatic system disorders</span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span></dd>
</dl>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></dd>
</dl>
<p><span class="Bold Italics">General disorders and administration site conditions</span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4319318" conceptname="Injection site inflammation">Injection site inflammation</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4316203" conceptname="Injection site hypersensitivity">Injection site hypersensitivity</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></dd>
</dl>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsion</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></dd>
</dl>
<p><span class="Bold Italics">Skin and subcutaneous tissue disorders</span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></dd>
</dl>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pallor</span></dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Concomitant Administration With Other Vaccines</h2>
<p class="First">No safety and immunogenicity data are available on the concomitant administration of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed with other US licensed vaccines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Concomitant Administration with <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Immune Globulin (Human)</h2>
<p class="First">If passive protection against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> is required, TIG (Human) may be administered according to its prescribing information, concomitantly with <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed at a separate site with a separate needle and syringe.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3	Immunosuppressive Treatments</h2>
<p class="First">Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed. [See <span class="Italics"><a href="#S5.4">Warnings and Precautions (5.4)</a>.</span>]</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category C</span></p>
<p>Animal reproduction studies have not been conducted with <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed. It is also not known whether <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.</p>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.2"></a><p></p>
<h2>8.4 	Pediatric Use</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed is not indicated for infants below 6 weeks of age or children 7 years of age or older. Safety and effectiveness of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed in these age groups have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed is a sterile, cloudy, white, uniform suspension of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoids adsorbed on aluminum phosphate and suspended in isotonic sodium chloride solution for intramuscular injection only. <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed vaccine does not contain a preservative.</p>
<p>Each 0.5 mL dose is formulated to contain: 25 Lf <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid and 5 Lf <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid. Other ingredients per 0.5 mL dose include: 1.5 mg aluminum phosphate and &lt;100 mcg free formaldehyde.</p>
<p><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> toxoid is prepared from the toxin produced during the growth of a selected <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Corynebacterium diphtheriae</span> grown with aeration in submerged culture. The toxin is purified by precipitation, converted to toxoid by the addition of formalin and concentrated by ultrafiltration. The culture medium consists of a tryptic digest of casein, supplemented with cystine, maltose, uracil, inorganic salts and vitamins.</p>
<p><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> toxoid is prepared from the toxin produced during the growth of a selected <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Clostridium tetani.</span> The toxin is converted to toxoid by the addition of formalin, concentrated and then purified. The culture medium consists of a tryptic digest of casein, supplemented with cystine, dextrose, uracil, inorganic salts and vitamins.</p>
<p>When tested in guinea pigs, the <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> components induce at least 2 neutralizing units/mL of serum.</p>
<p>The vial stopper is not made with natural rubber latex.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-10"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> is an acute toxin-mediated disease caused by toxigenic <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. diphtheriae</span>. Protection against disease is due to the development of neutralizing antibodies to <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxin. A serum <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> antitoxin level of 0.01 International Units (IU)/mL is the lowest level giving some degree of protection, and levels of at least 0.1 IU/mL are generally regarded as protective. (3) (4)</p>
<p><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> is an acute disease caused by an extremely potent neurotoxin produced by <span class="Italics">C. tetani</span>. Protection against disease is due to the development of neutralizing antibodies to <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxin. A serum <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antitoxin level of 0.01 IU/mL, measured by neutralization assay is considered the minimum protective level. (3) (5)</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-11"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-11.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed has not been evaluated for carcinogenicity, mutagenic potential, or impairment of fertility.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-12"></a><p></p>
<h1>14	CLINICAL STUDIES</h1>
<p class="First">In a clinical study conducted in Baltimore, MD, infants received one of three lots of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed (formulation that contained thimerosal), 0.5 mL, at 2, 4 and 6 months of age. Oral poliovirus vaccine (no longer licensed in the US) was administered concomitantly with <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed at 2 and 4 months of age. <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antitoxin levels were evaluated at 8 months of age (see<a href="#table2"> Table 2</a>). Protective levels of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> antitoxin (≥0.01 IU/mL) and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antitoxin (≥0.01 IU/mL) were detected in 99% and 100%, respectively, of the <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed recipients after 3 doses. The geometric mean titres (GMT's) for <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antitoxin antibodies in recipients of the three <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed lots were not significantly different, ranging from 0.25 to 0.35 IU/mL for <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> antitoxin antibodies, and from 0.75 to 0.80 IU/mL for <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antibodies after the third dose. In a fourth group of 75 infants who received an investigational acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> vaccine simultaneously with the <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed but at separate sites with separate needles and syringes, protective <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antitoxin levels developed in 100% of the recipients.</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2: Percentage of Children Protected Following Administration of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed </span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="70%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Post Dose 3 <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> antitoxin ≥0.01 IU/mL</td>
<td class="Rrule" align="center">99% (135/136)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> antitoxin ≥0.01 IU/mL</td>
<td class="Rrule" align="center">100% (137/137)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-13"></a><p></p>
<h1>15	REFERENCES</h1>
<dl>
<dt>1</dt>
<dd>Adverse Events Associated with Childhood Vaccines. Institute of Medicine. 1994.</dd>
<dt>2</dt>
<dd>Scheifele D, et al. Role of whole-cell <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> vaccine in severe local reactions to the preschool (fifth) dose of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span>-<span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span>-<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> vaccine. Can Med Assoc Journal 1994;150(1).</dd>
<dt>3</dt>
<dd>Department of Health and Human Services, Food and Drug Administration. Biological products; bacterial vaccines and toxoids; implementation of efficacy review; proposed rule. Federal Register 1985;50(240):51002-117.</dd>
<dt>4</dt>
<dd>Vitek CR, Wharton M. <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> toxoid. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 5th ed. Philadelphia, PA: W. B. Saunders; 2008. p. 139-56.</dd>
<dt>5</dt>
<dd>Wassilak SGF, et al. <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> toxoid. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 5th ed. Philadelphia, PA: W.B. Saunders; 2008. p. 805-39.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed is supplied in:<br>a 0.5 mL single dose vial: NDC No. 49281-225-58;<br>in packages of 10 vials: NDC No. 49281-225-10.</p>
<p>The vial stopper is not made with natural rubber latex.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed should be stored at 2° to 8°C (35° to 46° F).<span class="Bold"> Do not freeze</span>. Product which has been exposed to freezing should not be used. Do not use vaccine beyond the expiration date.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<p class="First">Inform the parent or guardian of the following:</p>
<ul>
<li>It is important to complete the immunization series for maximum protection against <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>.</li>
<li>Common adverse reactions include local <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> at the injection site, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, and loss of appetite.</li>
<li>Other adverse reactions can occur. Call your healthcare provider with any adverse reactions of concern.</li>
<li>Provide the Vaccine Information Statements (VIS), which are required by the National Childhood Vaccine Injury Act of 1986.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Manufactured by:<br><span class="Bold">Sanofi Pasteur Limited</span><br>Toronto Ontario Canada</p>
<p>Distributed by:<br><span class="Bold">Sanofi Pasteur Inc.</span><br>Swiftwater PA 18370 USA</p>
<p>R5-0613 USA</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 0.5 mL Vial Label</span></p>
<p>NDC<span class="Bold"> 49281-225-58<br>DT</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span><br>and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span><br>Toxoids<br>Adsorbed</span></p>
<p><span class="Italics">Rx only</span></p>
<p>For 6 wks - 6 yrs of age<br>Dose: 0.5 mL IM only</p>
<p><span class="Bold">Sanofi Pasteur Limited</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 0.5 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce88effe-7ff2-418f-acb3-3cb5d5d2bf95&amp;name=adsorbe-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 10 Vial Carton</span></p>
<p>NDC<span class="Bold"> 49281-225-10<br>DT</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and<br><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids<br>Adsorbed</span></p>
<p>For children 6 weeks<br>through 6 years of age</p>
<p><span class="Bold">10 </span>VIALS<br><span class="Bold">1 </span>Dose<br>each</p>
<p><span class="Italics">Rx only</span></p>
<p><span class="Bold">SANOFI </span>PASTEUR</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce88effe-7ff2-418f-acb3-3cb5d5d2bf95&amp;name=adsorbe-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">DIPHTHERIA</span> AND <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> TOXOIDS ADSORBED 		
					</strong><br><span class="contentTableReg">corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) and clostridium tetani toxoid antigen (formaldehyde inactivated) injection, suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">VACCINE LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49281-225</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</strong> (CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)) </td>
<td class="formItem">CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</td>
<td class="formItem">25 [Lf]  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</strong> (CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)) </td>
<td class="formItem">CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</td>
<td class="formItem">5 [Lf]  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM PHOSPHATE</strong></td>
<td class="formItem">1.5 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FORMALDEHYDE</strong></td>
<td class="formItem">100 ug  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (CLOUDY) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49281-225-10</td>
<td class="formItem">10  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49281-225-58</td>
<td class="formItem">0.5 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103944</td>
<td class="formItem">03/29/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sanofi Pasteur Inc.
							(086723285)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi Pasteur Limited</td>
<td class="formItem"></td>
<td class="formItem">208206623</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>71231ab7-9fcd-4f58-a860-54a74a480569</div>
<div>Set id: ce88effe-7ff2-418f-acb3-3cb5d5d2bf95</div>
<div>Version: 5</div>
<div>Effective Time: 20130626</div>
</div>
</div> <div class="DistributorName">Sanofi Pasteur Inc.</div></p>
</body></html>
